NorthStrive Biosciences Advances to Phase III of AI-Driven Drug Discovery Program Toward Validation of Multiple Potential Drug Compounds & Discoveries

Phase III is intended to generate meaningful biological data on potential drug compounds prioritized by YuvaBio’s classifier, which applies proprietary machine-learning methods to identify candidates targeting muscle preservation through improvements in mitochondrial function.Experimental work designed to identify candidates that may upregulate ANT1, a key gene involved in metabolic function and muscle integrity.Phase III is expected to accelerate discovery on small-molecule candidates which may promote mit ...